|
|
||||||||
Brief Communications |
Correspondence: 1Corresponding Author: Christina Puff, Department of Pathology, University of Veterinary Medicine Hannover, Bünteweg 17, D-30559 Hannover, Germany. Christina.Puff{at}tiho-hannover.de
| Abstract |
|---|
|
|
|---|
Key Words: Horses lymphangiosarcoma nictitating membrane tumor ultrastructural findings
Ocular tumors of vascular origin have been rarely described in horses.1,4,9,13 Such tumors include hemangiomas, hemangiosarcomas, and lymphangiosarcomas.1,13 In cases where the cell of origin remains undetermined, they are classified as angiosarcomas.4,9
Lymphangiosarcoma is an extremely rare tumor originating from the lymphatic endothelium.5 It occurs in various species and is most frequently described in dogs16 and cats.6 Additionally, single cases are reported in horses7,12 and cattle.11 In domestic animals, lymphangiosarcomas tend to be localized in the subcutis along the ventral midline and limbs.5 Grossly, these neoplasms are poorly demarcated, soft to spongy masses, containing clear, serous fluid on cut surface.3 Histologically, lymphangiosarcomas differ little from their benign counterpart, except for their increased cellular pleomorphism. Characteristic features include clefts and channels lined with cells displaying more rounded nuclei with hyperchromatism and a slightly increased mitotic activity.5 The underlying cause triggering the development of lymphangiosarcomas remains undetermined in most cases. However, chronic lymphedema has been shown to play an important role in humans.15
A 15-year-old Haflinger gelding showed a swelling of the left nictitating membrane of 4 weeks' duration. A biopsy of this cavernous, fluid-filled mass was taken and sent for histopathologic examination. Two weeks later, a total extirpation of the nictitating membrane was performed. Postoperatively, the horse developed a progressive periocular swelling and a sero-sanguinous nasal discharge over the following 5 months. Therefore, a second biopsy was taken. As a result of poor prognosis, the horse was euthanized but was not available for postmortem examination.
For histopathologic examination, biopsies were fixed in 10% neutral nonbuffered formalin and embedded in paraffin wax. Tissue sections were stained with hematoxylin and eosin, periodic acid Schiff (PAS), and elastic van Gieson (EVG). Additional sections were used for immunohistochemistry by applying the avidin–biotin complex method using primary antibodies directed against vimentina and factor VIII–related antigenb as described.8 Briefly, sections were dewaxed, and antigens were demasked by Triton treatment (vimentin; 0.25%, 30 min) and Pronase E treatment (factor VIII–related antigen; 20 min).8 For electron microscopy, formalin-fixed tissue was postfixed in 5% glutaraldehyde and 1% osmium acid, and embedded in Epon. Thin sections were stained with lead citrate and uranyl acetate.
Histologic examination of both the biopsies and the extirpated nictitating membrane revealed a densely cellular, poorly demarcated, diffusely infiltrating, unencapsulated mass, which in some areas extended to the cut borders. The tumor cells were arranged in intimate association to collagen bundles, which stained red with EVG. The neoplastic cells formed clefts and numerous, anastomosing, in some areas markedly dilated, vascular channels. An incontinuity and multifocal absence of the basal lamina were observed in the PAS stain. Tumor cells were flattened to polygonal, measuring 10 to 25 µm in diameter. They had indistinct cell borders and a moderate amount of a homogeneous, eosinophilic cytoplasm. The eccentrically located, round to oval nucleus showed a finely stippled chromatin pattern with hyperchromasia in single nuclei. Each nucleus contained 1 to 2 basophilic nucleoli. There was a moderate cellular pleomorphism present (Fig. 1) and up to 1 mitotic figure per high power field detectable. The periphery of the neoplasm showed a moderate, diffuse infiltration of lymphocytes and macrophages with lymph follicle–like lymphoid aggregates in the peritumoral area. Additionally, there was a marked lymphangiectasia, characterized by flattened endothelia, in the nontumorous area of the nictitating membrane.
|
Ultrastructural analysis showed empty clefts lined by neoplastic cells without a basement membrane between the tumor cells and the adjacent stroma (Fig. 2). The cells consisted of a round to oval nucleus, a paranuclear zone rich in intermediate filaments, and slightly eccentrically placed mitochondria (Fig. 3). Based on the histopathologic, immunohistochemical, and ultrastructural features a lymphangiosarcoma was diagnosed.
|
|
In humans and in dogs, most cases of lymphangiosarcoma had a history of prolonged lymphedema at the tumor site, suggesting that the constant protein-rich interstitial fluid might be a stimulus for neoplastic transformation.15,16 In the present case there was no known history of chronic lymphedema. The differentiation between lymphangiomas and lymphangiosarcomas can be critical as they only differ in their cellular pleomorphism.5 Another challenge is the discrimination between hemangiosarcomas and lymphangiosarcomas, which is mainly based on the apparent close apposition of neoplastic cells to collagen bundles and the lack of blood cells in the channels and clefts in the latter.3 As in the present case, the expression of factor VIII–related antigen and vimentin has been reported in lymphangiosarcomas of various species, including the horse.7,12 Similarly, as in the present case, a lack of the basement membrane between the neoplastic cells and the underlying collagen bundles as determined by electron microscopy represent a key feature to confirm the lymphatic histogenesis.7,14 In conclusion, this report describes for the first time a lymphangiosarcoma in the nictitating membrane of a horse.
| Acknowledgments |
|---|
| Sources and manufacturers |
|---|
|
|
|---|
a. Mouse-anti-vimentin, monoclonal, DAKO cytomation, Glostrup, Denmark. ![]()
b. Mouse-anti-human, polyclonal, DAKO cytomation, Glostrup, Denmark. ![]()
| References |
|---|
|
|
|---|
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |